Novo Nordisk, the world leader in diabetes care has introduced a special Improve Control Mobile Clinic in India. The Mobile Clinic is part of an initiative by Novo Nordisk to take diabetes care to the grass root level in the country.

The clinic based in Bangalore would initially cover a radius of 150 kilometer in a three-month pilot project. The effort would be scaled up in the next phase beginning March 2008 to extend the reach of the clinic across Karnataka. In phase III, Novo Nordisk expects to introduce Mobile Clinics in India to cover the regions in and around New Delhi, Mumbai, Chennai and Kolkata.

The Clinic in India is part of the global initiative by Novo Nordisk in taking diabetes care to people from different walks of life and ensuring that diabetes screening becomes an integral part in improving diabetes care in India. The van designed to deliver high standards in detection and treatment facilitation.

Equipped with blood glucose monitoring systems, weight check and body mass index platforms and patient education audio-visuals, the improve control mobile clinic will encourage doctors along its route to leverage facilities within the bus to monitor and ensure better glycaemia control of people in their respective regions. A computerized data management centre in the Mobile Clinic will provide a treatment score-card for patients as determined by the attending doctors.

The Improve Control Mobile Clinic was unveiled by Melvin Oscar D'Souza, Managing Director, Novo Nordisk (India) Private Limited in the presence of Thomas Thestrup-Terp, International Marketing Manager, Novo Nordisk, Denmark.

Melvin D'Souza, managing director said, " As part of a Novo Nordisk global initiative, the Improve Control programme was activated in India in April this year with a direction set to improving patient care through large scale diabetes education programmes and scaling up medical knowledge in enhanced treatment modalities".

Thomas Thestrup-Terp, international marketing manager, Novo Nordisk, said, " the Improve Control Programme in India has already met with initial success and we will further strengthen our efforts in taking diabetes care to a wider audience much in need of attention".

Novo Nordisk has registered a 15 per cent annual growth in India and with 52 per cent of the world's volume market share. The company's one of the main growth drivers is the Novo Nordisk International Operations which is also headquartered in India. Sales in India have been consistently growing with Novo Nordisk delivering over 15 million insulin vials to diabetics across India.